While kinase domain mutations are the most common mechanism of therapy resistance in CML, BCR::ABL1 amplification is also common and can overtake the inhibitory capacity of TKIs by simply out numbering the drug [31]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.